Evidence map›Paper›PMID 40984121›Full record

ArticleMilitary medicine2025

A Novel, Reverse-Phase-Shifting, Thermoreversible Foaming Hydrogel Containing Antibiotics for the Treatment of Traumatic Tissue Injuries in a Swine Model.

Ross I Donaldson, Aslam A Akhtar, Arghavan Farzadi, Todd L Graham, Jonathan K Armstrong, Oliver J Buchanan, John S Cambridge, Nely N Cristerna, Diane Goldenberg, Juliana Tolles and 2 more

Abstract read
In one paragraph

Article in Military medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ross I DonaldsonCritical Innovations LLC, Los Angeles, CA 90260, USA.
Aslam A AkhtarDepartment of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, CA 90509, USA.
Arghavan FarzadiCritical Innovations LLC, Los Angeles, CA 90260, USA.
Todd L GrahamBenchmark Biotech LLC, Portland, OR 97232, USA.
Jonathan K ArmstrongCritical Innovations LLC, Los Angeles, CA 90260, USA.
Oliver J BuchananCritical Innovations LLC, Los Angeles, CA 90260, USA.
John S CambridgeCritical Innovations LLC, Los Angeles, CA 90260, USA.
Nely N CristernaCritical Innovations LLC, Los Angeles, CA 90260, USA.
Diane GoldenbergCritical Innovations LLC, Los Angeles, CA 90260, USA.
Juliana TollesDepartment of Emergency Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Maja EnglerBenchmark Biotech LLC, Portland, OR 97232, USA.
James D RossBenchmark Biotech LLC, Portland, OR 97232, USA.

Funding

Department of DefenseSmall Business Innovation ResearchSmall Business Technology Transfer W81XWH22C0013U.S. Army Medical Research Development Command
6 · The paper itself

Abstract

introductionMore than one-third of patients with a combat injury evacuated to the United States have wound-related infections during their initial hospitalization, with prevention of such infections an ongoing battlefield challenge. Use of a reverse-phase-shifting thermoreversible foaming hydrogel containing vancomycin and tobramycin (HA) is one possible solution to this problem. MATERIALS AND

methodsThis study compared HA to the hydrogel vehicle without antibiotics (HV) and control (i.e., no intervention). Bilateral, 5 cm diameter, full-thickness wounds were created in 12 male swine (∼50 kg, Sus scrofa). These wounds were then inoculated with Staphylococcus aureus and Pseudomonas aeruginosa. Ten minutes after inoculation, the wounds were treated with HA, HV, or no intervention. This treatment was reapplied daily for a total of 7 days. Blood samples were drawn at baseline, 1 h after initial administration, and on days 1, 3, and 7. After 7 days, the animals were humanely euthanized and the wounds were swabbed or biopsied for microbiological analysis and culture. Full-thickness tissue specimens were subsequently collected for blinded histopathological evaluation of wound healing and bacterial growth.Institutional Animal Care and Use Committee and the U.S. Army's Animal Care and Use Review Office approvals were received prior to initiation of animal experiments.

resultsBacterial growth and histopathology analyses of cutaneous and skeletal muscle biopsies at the end of the study showed less severe and/or less frequent intralesional bacterial and neutrophilic inflammation in the HA group compared to the HV and control groups. The HV and control groups were comparable, showing no significant differences in treatment effects. Statistical significance was observed in reduced bacterial infiltration when comparing the HA group with both the control and HV groups. Neither vancomycin nor tobramycin was detected systemically in any plasma sample at all time points, with a lower limit of quantification of 50 ng/mL for both antibiotics.

conclusionHistopathology demonstrated significantly lower bacterial growth in the HA versus control (P = 1.4e-4) and HV (P = 3.2e-4) groups. It also showed statistically significant differences in other secondary outcomes for wound healing (e.g., neutrophilic infiltrate, fibroplasia, edema) between HA versus HV, as well as HA versus control, in both skin and muscle. In this porcine model of infected traumatic soft tissue injury, HA demonstrated significant benefits, and further research and development to explore its use in a range of settings is justified.

Indexed as

Anti-Bacterial AgentsHydrogelsWounds and InjuriesAnimalsDisease Models, AnimalMalePseudomonas aeruginosaStaphylococcus aureusSwineTobramycinVancomycinWound HealingWound InfectionAnti-Bacterial AgentsHydrogelsTobramycinVancomycin

Identifiers

PMID40984121
PMCPMC12448689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.